Reaching Others University at Buffalo - The State University of New York
Skip to Content
William                        Jusko

William J. Jusko PhD

Department of Pharmaceutical Sciences

Department Chair, Distinguished Professor

Specialty/Research Focus

pharmacodynamic; pharmacogenomics; pharmacokinetic; PK/PD

 
top-left cornertop-right corner
Professional Summary:

Research interests are in theoretical, basic, and clinical aspects of the pharmacokinetics and pharmacodynamics of various immunosuppressive agents including corticosteroids, as well as drugs used to treat diabetes, inflammation, and cancer. With Drs. Richard Almon and Debra DuBois, Dr. Jusko delves into the pharmacogenomics of diverse effects of corticosteroids and has evolved advanced mathematical models of receptor/gene-mediated responses. They have characterized the effects of corticosteroids on hepatic and muscle enzymes and tissue responses and have evolved advanced PK/PD models for cascade-type processes. Dr. Jusko has developed mechanism-based pharmacokinetic, pharmacodynamic, and disease progression models and computational methods describing the action of various drugs and utilizes mathematical models of drug action to determine optimal dosage regimens diverse drugs.

Education and Training:
  • PhD, State University of New York at Buffalo (1970)
  • BS, State University of New York at Buffalo (1965)
  • Secondary Education High School Diploma, Salamanca High School (1960)
Employment:
  • Director, Clinical Pharmacokinetics Laboratory (1972–1981)
  • Visiting Scientist (1978–1979)
  • Visiting Scientist (1978)
  • Assistant Professor of Pharmaceutics (1972–1974)
  • Director, Clinical Pharmacokinetics Laboratory (1972)
  • Assistant Professor of Pharmaceutics (1972)
  • Assistant Professor of Pharmacology (1970–1972)
  • Research Associate (1969–1972)
  • Research Pharmacologist (1969–1972)
  • Assistant Professor of Pharmacology (1970)
  • Research Pharmacologist (1969)
  • Research Associate (1969)
  • Research Assistant (1962–1969)
  • Pharmacist (1966–1968)
  • Pharmacist (1966)
  • Hospital Pharmacist (1962–1966)
  • Research Assistant (1962)
  • Hospital Pharmacist (1962)
See All (18 Total) >
Awards and Honors:
  • Sheiner-Beal Pharmacometrics Award (2013)
  • Advisor: AAPS Graduate Student Award in PPDM - Hoi Kei Lon (2012)
  • 2012 Distinguished Investigator Award (2012)
  • ACoP Award, Received the first ACoP Leadership Award at the American Conference on Pharmacometrics Meeting, San Diego, CA (2011)
  • AAPS Meritorious Manuscript Award (2008)
  • Distinguished Professor (2008)
  • Paul Ehrlich Magic Bullet Lifetime Achievement Award (2008)
  • Distinguished Professor (2007)
  • Swintosky Distinguished Lecturer (2006)
  • Volwiler Research Achievement Award (2005)
  • MERIT Award (2005)
  • Roland T. Lakey Award Lecture (2003)
  • ISI Most Highly Cited List in Pharmacology (2003)
  • Chancellor's Award (2003)
  • Sustained Achievement Award (2002)
  • John G. Wagner Lectureship (1999)
  • Research Achievement Award in PPDM, AAPS (1998)
  • Kosciusko Award (1996)
  • Faculty Exchange Scholar (1990)
  • Distinguished Service Award (1989)
  • Fellow (1989)
  • Russell R. Miller Award (1988)
  • Rawls-Palmer Award (1987)
  • Doctor Honoris Causae (1987)
  • Citizen of the Year (1987)
  • Fellow (1986)
  • Fellow (1985)
  • Fellow (1980)
  • Rorer Award (1980)
  • Fulbright-Hays Award to lecture/research in Milan, Italy (1978)
  • University Professor (1977)
  • Who's Who (various venues)
  • American Men and Women of Science

Research Expertise:
  • : Theoretical, basic, and clinical aspects of the PK/PD of immunosuppressive agents including corticosteroids, sirolimus, and tacrolimus
  • : Pharmacogenomics of diverse effects of corticosteroids and the development of models of receptor/gene-mediated responses
  • : Mechanism-based PK/PD models and computational methods describing the action of various drugs including PK/PD models of hematopoiesis characterizing stimulatory effects of growth factors and cytotoxicity of anticancer agents.
  • : Development of a compendium with comparison of the array of relevant mechanism-based PK/PD models
  • : Development of indirect response models with a precursor compartment including the occurrence of feedback alterations; evolution of extended indirect lifespan models for application to natural cell responses including effects such as bone marrow stimulation and/or cytotoxicity
  • : Detailed characterization of nonlinear and time-dependent transduction models which may be applied to numerous membrane receptor (e.g., G-protein) mediated responses.
Grants and Sponsored Research:
  • June 2012–August 2013
    Pharmacokinetics and Relative Bioavailability of Liquid Formulation of Hydroxyurea in Pediatric Patients with Sickle Cell Anemia
    Duke University
    Role: Principal Investigator
    $19,439
Patents:
  • Novel Method of Treatment (1999)

Evaluative Studies and Case Reports:
  • Rose JQ, Choi HK, Schentag JJ, Kinkel WR, Jusko WJ. Intoxication caused by interaction of chloramphenicol and phenytoin.. JAMA. 1977; 237(24).
Journal Articles:
  • Liu D; Lon H; Wang Y; Dubois DC; Almon RR; Jusko WJ. Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats. Biopharmaceutics & Drug Disposition. 2013; 34.
  • Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ. Physiologically-Based Pharmacokinetic Models for Everolimus and Sorafenib in Mice. Cancer Chemotherapy and Pharmacology. 2013; 71.
  • Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ. Synergistic Interactions Between Sorafenib and Everolimus in Pancreatic Cancer Xenografts in Mice. Cancer Chemotherapy and Pharmacology. 2013; 71.
  • Pawaskar DK; Straubinger RM; Fetterly GJ; Ma WW; Jusko WJ. Interactions of Everolimus and Sorafenib in Whole Blood Lymphocyte Proliferation. Pharmaceutical Research. 2013; 30.
  • Dubois DC; Sukumaran S; Jusko WJ; Almon RR. Evidence for a Glucocorticoid Receptor Beta Splice Variant in the Rat and Its Physiological Regulation in Liver Steroids. Steroids. 2013; 78.
  • Pawaskar DK; Straubinger RM; Fetterly GJ; Ma WW; Jusko WJ. Interactions of Everolimus and Sorafenib in Pancreatic Cancer Cells. AAPSJ. 2013; 15.
  • Fang J; Landersdorfer CB; Cirincione B; Jusko WJ. Study Reanalysis Using a Mechanism-Based Pharmacokinetic/Pharmacodynamic Model of Pramlintide in Subjects with Type 1 Diabetes. AAPSJ. 2013; 15.
  • Cao Y; Jusko WJ. Applications of Minimal Physiologically-Based Pharmacokinetic Models. Journal of Pharmacokinetics & Pharmacodynamics. 2012; 39.
  • Almon RR; Dubois DC; Sukumaran S; Wang X; Xue B; Nie J; Jusko WJ. Effects of High Fat Feeding on Liver Gene Expression in Diabetic Goto-Kakizaki Rats. Gene Regulation and Systems Biology. 2012; 6.
  • Lon H; Liu D; Jusko WJ. Pharmacokinetic/Pharmacodynamic Modeling in Inflammation. Critical Reviews in Biomedical Engineering. 2012; 40.
  • Sukumaran S; Lepist E; Dubois DC; Almon RR; Jusko WJ. Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone Effects on iNOS mRNA Expression and Nitric Oxide During LPSInduced Inflammation in Rats. Pharmaceutical Research. 2012; 29.
  • Cao Y; Dubois DC; Almon RR; Jusko WJ. Pharmacokinetics of salsalate and salicylic acid in normal and diabetic rats. Biopharmaceutics & Drug Disposition. 2012; 33.
  • Jusko WJ. Use of Pharmacokinetic Data Below Lower Limit of Quantitation Values. Pharmaceutical Research. 2012; 29.
  • Gao W; Jusko WJ. Modeling Disease Progression and Rosiglitazone Intervention in Type 2 Diabetic Goto-Kakizaki Rats. Journal of Pharmacology & Experimental Therapeutics. 2012; 341.
  • Gao W; Jusko WJ. Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys and Man. Drug Metabolism & Disposition. 2012; 40.
  • Landersdorfer CB; He Y; Jusko WJ. Mechanism-Based Population Modelling of the Effects of Vildagliptin on GLP-1, Glucose and Insulin in Patients with Type 2 Diabetes. British Journal of Clinical Pharmacology. 2012; 73.
  • Landersdorfer CB; He Y; Jusko WJ. Mechanism-Based Population Pharmacokinetic Modelling in Diabetes: Vildagliptin as a Tight Binding Inhibitor and Substrate of Dipeptidyl Peptidase IV. British Journal of Clinical Pharmacology. 2012; 73.
  • Cao Y; Jusko WJ. Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats. Pharmaceutical Research. 2012; 29.
  • Cao Y; Dubois DC; Sun H; Almon RR; Jusko WJ. Modeling Diabetes Disease Progression and Salsalate Intervention in Goto-Kakizaki Rats. Pharmaceutical Research. 2011; 339.
  • MA,ller JB; Jusko WJ; Gao W; Hansen T; Pedersen O; Holst JJ; Overgaard RV; Madsen H; Ingwersen SH. Mechanism-Based Population Modelling for Assessment of L-Cell Function Based on Total GLP-1 Response Following an Oral Glucose Tolerance Test. Journal of Pharmacokinetics and Pharmacodynamics. 2011; 38.
  • Liu D; Lon H; Dubois DC; Almon RR; Jusko WJ. Population Pharmacokinetic - Pharmacodynamic - Disease Progression Model for Effects of Anakinra in Lewis Rats with Collagen-Induced Arthritis. Journal of Pharmacokinetics and Pharmacodynamics. 2011; 38.
  • Sukumaran S; Jusko WJ; Dubois DC; Almon RR. LIGHT/ DARK OSCILLATIONS IN THE LUNG TRANSCRIPTOME: IMPLICATIONS 2 FOR LUNG HOMEOSTASIS, REPAIR, METABOLISM, DISEASE AND DRUG 3 ACTION. J Appl Physiol. 2011; 110.
  • Nie J; Bai B; Sukumaran S; Jusko WJ; Dubois DC; Almon RR. Differential Muscle Gene Expression as a Function of Disease Progression in Goto-Kakizaki Diabetic Rats. Molecular and Cellular Endocrinology. 2011; 338.
  • Fang J; Dubois DC; He Y; Almon RR; Jusko WJ. Dynamic modeling of methylprednisolone effects on body weight and glucose regulation in rats. J Pharmacokinet Pharmacodyn. 2011; 38.
  • Sukumaran S; Jusko WJ; Dubois DC; Almon RR. MECHANISTIC MODELING OF THE EFFECTS OF GLUCOCORTICOIDS AND CIRCADIAN RHYTHMS ON ADIPOKINE EXPRESSION. J. Pharmacol. Exp. Ther.. 2011; 337.
  • Lon H; Liu D; Zhang Q; Dubois DC; Almon RR; Jusko WJ. Pharmacokinetic-Pharmacodynamic Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-Induced Arthritis. Pharmaceutical Research. 2011; 28.
  • Bai JP; Meibohm B; Patterson SD; Puig O; Smerage JB; Snider BJ; Wagner JA; Wang J; Walton MK; Weiner R; Bell R; Buckman S; Burckart GJ; Eichler H; Fang KC; Goodsaid FM; Jusko WJ; Lesko LL. Translational Biomarkers: From Preclinical to Clinical, A Report of 2009 AAPS/ACCP Biomarker Workshop. The AAPS Journal. 2011; 13.
  • Xue B; Sukumaran S; Nie J; Jusko WJ; Dubois DC; Almon RR. Adipose Tissue Deficiency and Chronic Inflammation in Diabetic Goto-Kakizaki Rats. PLoS ONE. 2011; 6.
  • Gao W; Jusko WJ. Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats. THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 2011; 336.
  • Gao W; Bihorel S; Dubois DC; Almon RR; Jusko WJ. Mechanism-Based Disease Progression Modeling of Type 2 Diabetes in Goto-Kakizaki Rats. J Pharmacokinet Pharmacodyn. 2011; 38.
  • Scheff JD; Almon RR; Dubois DC; Jusko WJ; Androulakis IP. Assessment of Pharmacologic Area Under the Curve when Baselines are Variable. Pharmaceutical Research. 2011; 28.
  • Nie J; Dubois DC; Jusko WJ; Almon RR. Mechanistic Population Modeling of Diabetes Disease Progression in Goto-Kakizaki Rat Muscle. BIOPHARMACEUTICS & DRUG DISPOSITION. 2011; 32.
  • Ovacik MA; Sukumaran S; Almon RR; Dubois DC; Jusko WJ; Androulakis IP. Circadian Signatures in Rat Liver: From Gene Expression to Pathways. BMC Bioinformatics. 2010; 11.
  • Sukumaran S; Xue B; Jusko WJ; Dubois DC; Almon RR. Circadian variations in gene expression in rat abdominal adipose tissue and relationship to physiology. Physiol Genomics. 2010; 42A.
  • Jusko WJ; Ziegler A; Chatenoud C; Waldmann H; Hale G; Rebello P; Al Bakir I; Bolam E; Wiczling P; Vandemeulebroucke E; Keymeulen B; Mathieu C. Pharmacokinetics and Antibody Responses to the CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes. The Journal of Clinical Pharmacology. 2010; 50.
  • Scheff JD; Almon RR; Dubois DC; Jusko WJ; Androulakis IP. A New Symbolic Representation for the Identification of Informative Genes in Replicated Microarray Experiments. OMICS A Journal of Integrative Biology. 2010; 14.
  • Sukumaran S; Almon RR; Dubois DC; Jusko WJ. Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Advanced Drug Delivery Reviews. 2010; 62.
  • Nguyen TT; Almon RR; Dubois DC; Jusko WJ; Androulakis IP. Comparative Analysis of Acute and Chronic Corticosteroid Pharmacogenomic Effects in Rat Liver: Transcriptional Dynamics and Regulatory Structures. BMC Bioinformatics. 2010; 11.
  • Landersdorfer CB; Jusko WJ. Pharmacokinetic/Pharmacodynamic Modeling of Glucose Clamp Effects of Inhaled and Subcutaneous Insulin in Healthy Volunteers and Diabetic Patients. Drug Metab. Pharmacokinet.. 2010; 25.
  • Ghoshal S; Rao I; Earp JC; Jusko WJ; Wetzler M. Down-regulation of heat shock protein 70 improves arsenic trioxide and 17-DMAG effects on constitutive signal transducer and activator of transcription 3 activity. Cancer Chemotherapy Pharmacology. 2010; 66.
  • Nguyen TT; Almon RR; Dubois DC; Jusko WJ; Androulakis IP. Importance of replication in analyzing time-series gene expression data: Corticosteroid dynamics and circadian patterns in rat liver. BMC Bioinformatics. 2010; 11.
  • Wiczling P; Rosenzweig M; Vaickus L; Jusko WJ. Pharmacokinetics and Pharmacodynamics of a Chimeric/Humanized Anti-CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Subjects with Psoriasis and with Type 1 Diabetes Mellitus. Journal of Clinical Pharmacology. 2010; 50.
  • Bulitta JB; Yang JC; Yohonn L; Ly NS; Brown SV; D'Hondt RE; Jusko WJ; Forrest A; Tsuji BT. Attenuation of Colistin Bactericidal Activity by High Incoulum of Pseudomonas Aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy. 2010; 54.
  • Freishtat RJ; Nagaraju K; Jusko WJ; Hoffman EP. Glucocorticoid Efficacy in Asthma: Is Improved Tissue Remodeling Upstream of Anti-Inflammation. Journal of Investigative Medicine. 2010; 58.
  • Khinkis LA; Krzyzanski W; Jusko WJ; Greco WR. D-Optimal Designs for Parameter Estimation for Indirect Pharmacodynamic Response Models. J Pharmacokinet Pharmacodyn. 2009; 36.
  • Woo S; Pawaskar D; Jusko WJ. Methods of Utilizing Baseline Values for Indirect Response Models. J Pharmacokinet Pharmacodyn. 2009; 36.
  • Yang EH; Almon RR; Dubois DC; Jusko WJ; Androulakis IP. Identification of Global Transcriptional Dynamics. PLoS ONE. 2009; 4.
  • Cho H; Blum RA; Sunderland T; Cooper GJ; Jusko WJ. Pharmacokinetic and Pharmacodynamic Modeling of a Copper-Selective Chelator (TETA) in Healthy Adults. The Journal of Clinical Pharmacology. 2009; 49.
  • Almon RR; Dubois DC; Lai W; Xue B; Nie J; Jusko WJ. Gene expression analysis of hepatic roles in cause and development of diabetes in Goto-Kakizaki rats.. J Endocrinol. 2009; 200.
  • Landersdorfer CB; Dubois DC; Almon RR; Jusko WJ. Mechanism-based modeling of nutritional and leptin influences on growth in normal and type 2 diabetic rats.. J Pharmacol Exp Ther. 2009; 328.
  • Jin JY; Jusko WJ. Pharmacodynamics of Glucose Regulation by Methylprednisolone. II. Normal Rats. Biopharm. Drug Disp.. 2009; 30.
  • Mager DE; Woo S; Jusko WJ. Scaling Pharmacodynamics from In Vitro and Preclinical Animal Studies to Humans. Drug Metab. Pharmacokin.. 2009; 24.
  • Earp JC; Dubois DC; Almon RR; Jusko WJ. Quantitative dynamic models of arthritis progression in the rat.. Pharm Res. 2009; 26.
  • Bulitta JB; Ly NS; Yang JC; Forrest A; Jusko WJ; Tsuji BT. Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa. Antimicrob. Ag. Chemother.. 2009; 53.
  • Rohatagi S; Carrothers TJ; Jin J; Jusko WJ; Khariton T; Walker J; Truitt K; Salazar DE. Model-Based Development of a PPAR-gamma Agonist, Rivoglitazone, to Aid Dose Selection and Optimize Clinical Trial Designs. J Clin Pharmacol. 2008; 48.
  • Yao Z; Dubois DC; Almon RR; Jusko WJ. Pharmacodynamic/Pharmacogenomic Modeling of Insulin Resistance Genes in Rat Muscle After Methylprednisolone Treatment: Exploring Regulatory Signaling Cascades. Gene Reg. Sys. Biol.. 2008; 2.
  • Almon RR; Yang E; Lai W; Androulakis IP; Ghimbovschi S; Hoffman EP; Jusko WJ; Dubois DC. Relationships between circadian rhythms and modulation of gene expression by glucocorticoids in skeletal muscle.. Am J Physiol Regul Integr Comp Physiol.. 2008; 295.
  • Almon RR; Yang E; Lai W; Androulakis IP; Dubois DC; Jusko WJ. Circadian variations in rat liver gene expression: relationships to drug actions.. J Pharmacol Exp Ther. 2008; 326.
  • Earp JC; Dubois DC; Molan DS; Pyszcznski NA; Keller CE; Almon RR; Jusko WJ. Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. J. Pharmacol. Exp. Ther.. 2008; 326.
  • Earp JC; Dubois DC; Molano DS; Pyszczynski NA; Almon RR; Jusko WJ. Modeling corticosteroid effects in a rat model of rheumatoid arthritis II: mechanistic pharmacodynamic model for dexamethasone effects in Lewis rats with collagen-induced arthritis.. J Pharmacol Exp Ther.. 2008; 326.
  • Mager DE; Jusko WJ. Development of Translational Pharmacokinetic-Pharmacodynamic Models. Clin. Pharmacol. Ther.. 2008; 83.
  • Yao Z; Dubois DC; Almon RR; Jusko WJ. Pharmacodynamic/Pharmacogenomic Modeling of Insulin Resistance Genes in Rat Muscle After Methylprednisolone Treatment: Exploring Regulatory Signaling Cascades. Gene Regulation and Systems Biology. 2008; 2.
  • Yang E; Almon RR; Dubois DC; Androulakis IP; Jusko WJ. Extracting global system dynamics of corticosteroid genomic effects in rat liver. J Pharmacol Exp Ther. 2008; 324.
  • Hazra A; Dubois DC; Almon RR; Snyder GS; Jusko WJ. Pharmacodynamic Modeling of Acute and Chronic Effects of Methylprednisolone on Hepatic Urea Cycle Genes in Rats. Gene Regulation and Systems Biology. 2008; 2.
  • Woo S; Krzyzanski W; Jusko WJ. Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chem. Pharmacol.. 2008; 62.
  • Woo S; Krzyzanski W; Duliege A; Stead RR; Jusko WJ. Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers. J. Clin. Pharmacol.. 2008; 48.
  • Hazra A; Pyszczynski NA; Dubois DC; Almon RR; Jusko WJ. Modeling receptor/gene-mediated effects of corticosteroids on hepatic tyrosine aminotransferase dynamics in rats: dual regulation by endogenous and exogenous corticosteroids. J Pharmacokinet Pharmacodyn. 2007; 34.
  • Woo S; Krzyzanski W; Jusko WJ. Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J. Pharmacokin. Pharmacodyn.. 2007; 34.
  • Yao Z; Dubois DC; Almon RR; Jusko WJ. Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. J Pharm Sci. 2007; 97.
  • Hazra A; Dubois DC; Almon RR; Jusko WJ. Assessing the Dynamics of Nuclear Glucocorticoid-Receptor Complex: Adding Flexibility to Gene Expression Modeling. J. Pharmacokin. Pharmacodyn.. 2007; 34.
  • Tang E; Simcha D; Almon RR; Dubois DC; Jusko WJ; Androulakis IP. Context Specific Transcription Factor Prediction. Ann. Biomed. Eng.. 2007; 35.
  • Hong Y; Mager DE; Blum RA; Jusko WJ. Population pharmacokinetic/pharmacodynamic modeling of systemic corticosteroid inhibition of whole blood lymphocytes: Modeling interoccasion pharmacodynamic variability. Pharm Res. 2007; 24.
  • Almon RR; Dubois DC; Yao Z; Hoffman EP; Ghimbovschi S; Jusko WJ. Microarray analysis of the temporal response of skeletal muscle to methylprednisolone: comparative analysis of two dosing regimens. Physiol Genomics. 2007; 30.
  • Yao Z; Zhao B; Hoffman EP; Ghimbovschi S; Dubois DC; Almon RR; Jusko WJ. Application of Scaling Factors in Simultaneous Modeling of Microarray Data from Diverse Chips. Pharm. Res.. 2007; 24.
  • Wetzler M, Earp JC, Brady MT, Keng MK, Jusko WJ. Synergism between arsenic trioxide and heat shock protein 90 inhibitors on signal transducer and activator of transcription protein 3 activity--pharmacodynamic drug-drug interaction modeling. Clin Cancer Res. 2007; 13(7).
  • Almon RR; Dubois DC; Jusko WJ. A Microarray Analysis of the Temporal Response of Liver to Methylprednisolone: A Comparative Analysis of Two Dosing Regimens. Endocrinology. 2007; 148.
  • Krzyzanski W, Dmochowski J, Matsushima N, Jusko WJ. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models. J Pharmacokinet Pharmacodyn. 2006; 33(5).
  • Woo S; Krzyzanski W; Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.. Journal of Pharmacology and Experimental Therapeutics. 2006; 319.
  • Krzyzanski W; Dmochowski J; Matsushima N; Jusko WJ. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models.. Journal of Pharmacokinetics and Pharmacodynamics. 2006; 33.
  • Yao Z; Krzyzanski W; Jusko WJ. Assessment of basic indirect pharmacodynamic response models with physiological limits.. Journal of Pharmacokinetics and Pharmacodynamics. 2006; 33.
  • Krzyzanski W; Woo S; Jusko WJ. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.. Journal of Pharmacokinetics and Pharmacodynamics. 2006; 33.
  • Hon YY, Jusko WJ, Zhou HH, Chen GL, Guo D, Zhou G, Spratlin VE, Jann MW. Endogenous histamine and cortisol levels in subjects with different histamine N-methyltransferase C314T genotypes : a pilot study. Mol Diagn Ther. 2006; 10(2).
  • Mager DE; Neuteboom B; Jusko WJ. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res. 2005; 22.
  • Smith PF, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The influence of St. John‘s wort on the pharmacokinetics and protein bindingof imatinib mesylate. Pharmacotherapy. 2004; 24(11).
  • Almon RR, Chen J, Snyder G, DuBois DC, Jusko WJ, Hoffman EP. In vivo multi-tissue corticosteroid microarray time series available online at Public Expression Profile Resource (PEPR).. Pharmacogenomics. 2003; 4(6).
  • Mager DE; Lin SX; Blum RA; Lates CD; Jusko WJ. Dose equivalency evaluation of major corticosteroids: Pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol. 2003; 43.
  • Mager DE; Neuteboom B; Efthymiopoulos C; Munafo A; Jusko WJ. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta 1a in monkeys. J Pharmacol Exp Ther. 2003; 306.
  • Levy G; Mager DE; Cheung WK; Jusko WJ. Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci. 2003; 92.
  • Mager DE; Wyska E; Jusko WJ. Diversity of mechanism-based pharmacodynamic models. Drug Metab Disp. 2003; 31.
  • Mager DE; Pyszczynski NA; Jusko WJ. Integrated QSPR - pharmacodynamic model of genomic effects of several corticosteroids. J Pharm Sci. 2003; 92.
  • Mager DE; Jusko WJ. Quantitative structure-pharmacokinetic/pharmacodynamic relationships of corticosteroids in man. J Pharm Sci. 2002; 91.
  • Mager DE; Jusko WJ. Receptor-mediated pharmacokinetic/pharmacodynamic model of interferon-beta 1a in man. Pharm Res. 2002; 19.
  • Mager DE; Jusko WJ. Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther. 2001; 70.
  • Mager DE; Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001; 28.
  • Sutfin TA, Perini GI, Molnar G, Jusko WJ. Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients.. J Clin Psychopharmacol. 1988; 8(1).
  • Morphy MA, Fava GA, Carson SW, Perini GI, Molnar G, Jusko WJ. The metyrapone test in schizophrenic patients and healthy subjects.. Neuropsychobiology. 1985; 14(1).
  • Perini GI, Fava GA, Morphy MA, Carson SW, Molnar G, Jusko WJ. The metyrapone test in affective disorders and schizophrenia II. Changes upon treatment.. J Affect Disord. 1984; 7(3-4).
  • Fava GA, Carson SW, Perini GI, Morphy MA, Molnar G, Jusko WJ. The metyrapone test in affective disorders and schizophrenia.. J Affect Disord. 1984; 6(3-4).
  • Perini GI, Fava GA, Morphy MA, Carson SW, Molnar G, Jusko WJ. The metyrapone test in manic patients and healthy subjects.. Pharmacopsychiatry. 1984; 17(3).
  • Milsap RL, George DE, Szefler SJ, Murray KA, Lebenthal E, Jusko WJ. Effect of inflammatory bowel disease on absorption and disposition of prednisolone.. Dig Dis Sci. 1983; 28(2).
  • Szefler SJ, Brenner M, Jusko WJ, Spector SL, Flesher KA, Ellis EF. Dose- and time-related effect of troleandomycin on methylprednisolone elimination.. Clin Pharmacol Ther. 1982; 32(2).
  • Szefler SJ, Ellis EF, Brenner M, Rose JQ, Spector SL, Yurchak AM, Andrews F, Jusko WJ. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy.. J Allergy Clin Immunol. 1982; 69(5).
  • Rose JQ, Nickelsen JA, Ellis EF, Middleton E, Jusko WJ. Prednisolone disposition in steroid-dependent asthmatic children.. J Allergy Clin Immunol. 1981; 67(3).
  • Rocci ML, Szefler SJ, Acara M, Jusko WJ. Prednisolone metabolism and excretion in the isolated perfused rat kidney.. Drug Metab Dispos. 1981; 9(3).
  • Szefler SJ, Rose JQ, Ellis EF, Spector SL, Green AW, Jusko WJ. The Effect of Troleandomycin on Methylprednisolone Disposition. J Allergy Clin Immunol. 1980; 66(6).
  • Szefler SJ, Rose JQ, Ellis EF, Spector SL, Green AW, Jusko WJ. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol. 1980; 66(6).
  • Rose JQ, Nickelsen JA, Middleton E, Yurchak AM, Park BH, Jusko WJ. Prednisolone disposition in steroid-dependent asthmatics.. J Allergy Clin Immunol. 1980; 66(5).
  • MacKichan JJ, Jusko WJ, Duffner PK, Cohen ME. Liquid-chromatographic assay of diazepam and its major metabolites in plasma.. Clin Chem. 1979; 25(6).
  • Lima JJ, Conti DR, Goldfarb AL, Tilstone WJ, Golden LH, Jusko WJ. Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.. J Pharmacokinet Biopharm. 1979; 7(1).
  • Lima JJ, Goldfarb AL, Conti DR, Golden LH, Bascomb BL, Benedetti GM, Jusko WJ. Safety and efficacy of procainamide infusions.. Am J Cardiol. 1979; 43(1).
  • Plaut ME, Schentag JJ, Jusko WJ. Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients.. J Med. 1979; 10(4).
  • Schentag JJ, Cumbo TJ, Jusko WJ, Plaut ME. Gentamicin tissue accumulation and nephrotoxic reactions.. JAMA. 1978; 240(19).
  • Jusko WJ, Schentag JJ, Clark JH, Gardner M, Yurchak AM. Enhanced biotransformation of theophylline in marihuana and tobacco smokers.. Clin Pharmacol Ther. 1978; 24(4).
  • Lima JJ, Conti DR, Goldfarb AL, Golden LH, Jusko WJ. Pharmacokinetic approach to intravenous procainamide therapy.. Eur J Clin Pharmacol. 1978; 13(4).
  • Mangione A, Imhoff TE, Lee RV, Shum LY, Jusko WJ. Pharmacokinetics of theophylline in hepatic disease.. Chest. 1978; 73(5).
  • Schentag JJ, Lasezkay G, Plaut ME, Jusko WJ, Cumbo TJ. Comparative tissue accumulation of gentamicin and tobramycin in patients.. J Antimicrob Chemother. 1978; 4 Sup.
  • Schentag JJ, Lasezkay G, Cumbo TJ, Plaut ME, Jusko WJ. Accumulation pharmacokinetics of tobramycin.. Antimicrob Agents Chemother. 1978; 13(4).
  • Schentag JJ, Sutfin TA, Plaut ME, Jusko WJ. Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin.. J Med. 1978; 9(3).
  • Schentag JJ, Jusko WJ, Plaut ME, Cumbo TJ, Vance JW, Abrutyn E. Tissue persistence of gentamicin in man.. JAMA. 1977; 238(4).
  • Koup JR, Jusko WJ, Goldfarb AL. pH-dependent secretion of procainamide into saliva.. J Pharm Sci. 1975; 64(12).
  • Koup JR, Greenblatt DJ, Jusko WJ, Smith TW, Koch-Weser J. Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses.. J Pharmacokinet Biopharm. 1975; 3(3).
  • Jusko WJ, Szefler SJ, Goldfarb AL. Pharmacokinetic design of digoxin dosage regimens in relation to renal function.. J Clin Pharmacol. 1974; 14(10).
  • Jusko WJ, Rennick BR, Levy G. Renal exretion of riboflavin in the dog.. Am J Physiol. 1970; 218(4).
  • Plaut ME, Schentag JJ, Jusko WJ. Aminoglycoside nephrotoxicity: comparative assessment in critically ill patients.. J Med. ; 10(4).
  • Schentag JJ, Sutfin TA, Plaut ME, Jusko WJ. Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin.. J Med. ; 9(3).
See All (125 Total) >
Abstracts:
  • Morse ED; Janicke DM; Cafarell RF; Walshe JJ; Venuto RC; Apicella MA; Jusko WJ. Pharmacokinetics of intraperitoneal moxalactam in CAPD. Drug Intelligence & Clinical Pharmacy. 1984; 18.
Books and Book Chapters:
  • Sukumaran S; Dubois DC; Jusko WJ; Almon RR. Glucocorticoid Effects on Adiponectin Expression in Adiponectin. Adiponectin, Vitamins & Hormones Series. 2012; 90.
  • Mager DE; Jusko WJ. Mechanistic Pharmacokinetic/Pharmacodynamic Models II (Chapter 23). Pharmacometrics, The Science of Quantative Pharmacology. 2007.

Professional Memberships:
  • European Federation for Pharmaceutical Sciences (1999)
  • American College of Clinical Pharmacology (1989)
  • American Association of Pharmaceutical Scientists (1986)
  • Federation Internationale Pharmaceutique (1980)
  • American College of Clinical Pharmacy (1980)
  • American Society for Clinical Pharmacology and Therapeutics (1976)
  • American Society for Microbiology (1975)
  • American Society for Pharmacology and Experimental Therapeutics (1974)
  • American Association of Colleges of Pharmacy (1972)
  • American Association for the Advancement of Science (1970)
  • Rho Chi Pharmaceutical Honor Society (1968)
  • Kappa Psi Pharmaceutical Fraternity (1962)
  • American Pharmaceutical Association (1962)
Presentations:
  • "CELL CYCLE MODELING OFFERS A PLATFORM TO OPTIMIZE COMBINATION OF CYTARABINE AND FLT3 INHIBITORS IN ACUTE MYELOID LEUKEMIA" Congress of the European Hematology Association, 18th Congress of the European Hematology Association (2013)
  • "Evolution of Mechanistic PK/PD Modeling - Our Future?" ASCPT 2013 Annual Meeting, ASCPT (2013)
  • "PHARMACODYNAMIC MODELING OF CELL CYCLE EFFECTS OF CYTARABINE AND FLT3 INHIBITORS ON ACUTE MYELOID LEUKEMIA CELLS" ASCPT 2013 Annual Meeting, ASCPT (2013)
  • "Applications of Minimal Physiologically-Based Pharmacokinetic Models" Research Institute of Pharmaceutical Sciences, Seoul National University (SNU) (2012)
  • "Moving PK/PD from Basic Towards Systems Pharmacology" 2012 International Conference of the Korean Society of Pharmaceutical Sciences and Technology (KSPST), KSPST (2012)
  • "Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics: Lessons From Corticosteroids" The Catholic University of Korea School of Medicine, Korean Society of Clinical Pharmacology and Therapeutics (2012)
  • "Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics: Lessons From Corticosteroids" Biomedical Research Institute, Chonnam National University Hospital (CNHU) (2012)
  • "Application of Minimal Physiologically-based Pharmacokinetic Models" 2012 AAPS Annual Meeting and Exposition, AAPS (2012)
  • "Mechanism-based Population Pharmacokinetic and Pharmacodynamic Modeling of Intravenous and Intranasal Dexmedetomidine" 2012 AAPS Annual Meeting and Exposition, AAPS (2012)
  • "Modeling Effects of Dexamethasone on Disease Progression of Bone Mineral Density in Collagen-induced Arthritic Rats" 2012 AAPS Annual Meeting and Exposition, AAPS (2012)
  • "Population Pharmacokinetics Analysis of Orally Administrated Baclofen in Pediatric Patients with Cerebral Palsy" 2012 AAPS Annual Meeting and Exposition, AAPS (2012)
  • "Proteome-level Pharmacokinetic/Pharmacodynamic Analysis of Corticosteroid-responsive Proteins in Rat Liver" 2012 AAPS Annual Meeting and Exposition, AAPS (2012)
  • "Extensive, proteome-level investigation of the corticosteroid pharmacodynamics with 12 time points using a reproducible and comprehensive ion-current-based profiling strategy" HUPO 2012 11th Annual World Congress, HUPO (2012)
  • "Moving PK/PD from Basic towards Systems Pharmacology" 2012 American College of Clinical Pharmacology (ACCP) Annual Meeting, American College of Clinical Pharmacology (2012)
  • "Pharmacokinetics/Pharmacodynamics/Pharmacogenomics: Lessons from Corticosteroids" 2012 American College of Clinical Pharmacology (ACCP) Annual Meeting, American College of Clinical Pharmacology (2012)
  • "Prednisone Dose and Exposure in Chronic Renal Transplant Recipients: One Size Does NOT Fit All" American Transplant Congress, American Transplant Congress (2012)
  • "Take it With Breakfast: But Does Food Reduce Prednisone Exposure As Much As It Reduces CNI Exposure in Renal Transplant Patients?" American Transplant Congress, American Transplant Congress (2012)
  • "Effects of sonic hedgehog inhibitor combined with nanoparticulate drug delivery on vascular permeability and efficacy in a pancreatic cancer model." Annual Meeting of the American Association for Cancer Research, American Association for Cancer Research (2012)
  • "Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine" 4th Annual UB Postdoc Research Symposium, University at Buffalo (2012)
  • "Multi-scale assessment of Everolimus and Sorafenib Combination in Pancreatic Cancer" American Association for Cancer Research, AACR (2012)
  • "Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats" 4th Annual UB Postdoc Research Symposium, University at Buffalo (2012)
  • "Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone Effects on iNOS mRNA Expression and Nitric Oxide During LPS-Induced Inflammation in Rats" 4th Annual UB Postdoc Research Symposium, University at Buffalo (2012)
  • "PK/PD/Disease Modeling in Cancer Chemotherapy" Hoffman La Roche, Hoffman La Roche (2012)
  • "What We Do in Pharmaceutical Sciences" UB Biology Honors Program (2012)
  • "Moving PK/PD From Basic Towards Systems Pharmacology" Rosa & Co. Impact of Modeling & Simulation in Drug Development Webinar, Rosa & Co. LLC. (2011)
  • "Population PK and PD Analysis of Oral Baclofen in Pediatric Patients with Cerebral Palsy" Pediatric Neurology Cerebral Palsy Center, Pediatric Neurology Cerebral Palsy Center (2011)
  • "Mechanistic Modeling of Tissue-specific Effects of Corticosteroids and Circadian Rhythms on Phosphoenolpyruvate Carboxykinase Expression in Rat Liver and Adipose Tissue" 2011 AAPS Annual Meeting and Exposition, AAPS (2011)
  • "Modeling Diabetes Disease Progression and Salsalate Intervention in Goto-Kakizaski Rats" 2011 AAPS Annual Meeting and Exposition, AAPS (2011)
  • "Modeling Pharmacokinetics/Pharmacodynamics of Abatacept and Disease Progression in Collagen-induced Arthritic Rats - A Population Approach" 2011 AAPS Annual Meeting and Exposition, AAPS (2011)
  • "Population Pharmacokinetic-Pharmacodynamic-Disease Progression Model for Effects of Anakinra in Lewis Rats with Collagen-induced Arthritis" 2011 AAPS Annual Meeting and Exposition, AAPS (2011)
  • "Population Physiologically-based Pharmacokinetic Models for Everolimus and Sorafenib in Pancreatic Cancer Xenograft Mice" 2011 AAPS Annual Meeting and Exposition, AAPS (2011)
  • "Systems Pharmacological Analysis of Molecularly Targeted Agents in Pancreatic Cancer: Pharmacodynamic Design of Novel Therapeutic Trials" Clinical and Translational Research Colloquium, University at Buffalo (2011)
  • "The Relevance of Chronobiology in PK/PD" 2011 AAPS Annual Meeting and Exposition, AAPS (2011)
  • "Pharmacokinetic/Pharmacodynamic/Disease Progression Model of Anakinra, an Interleukin-1 Receptor Antagonist, in Collagen-Induced Arthritic Rats" Third Annual Symposium Center for Protein Therapeutics, University at Buffalo (2011)
  • "Pharmacokinetic/Pharmacodynamic/Disease Progression Model of Effects of Abatacept in Collagen-Induced Arthritic Rats" Third Annual Symposium Center for Protein Therapeutics, University at Buffalo (2011)
  • "Assessment of L-Cell Function Based on GLP-1 Response in an Oral Glucose Tolerance Test" 2011 PAGE Meeting, PAGE (2011)
  • "Modeling type 2 diabetes progression in newly diagnosed patients" Post-Doctoral Fellowship Day, University at Buffalo (2011)
  • "PK/PD Modeling of Drug Effects in Inflammation" Bristol Myers Squibb, Bristol Myers Squibb (2011)
  • "Population pharmacokinetic-pharmacodynamic-disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis" Post-Doctoral Fellowship Day, University at Buffalo (2011)
  • "Genome-wide analysis of circadian oscillations in gene expression in lung and its implications in lung homeostasis, repair and diseases" EXPERIMENTAL BIOLOGY 2011, APS (2011)
  • "Modeling Diabetes Progression in Goto-Kakizaki Rat and Salsalate Intervention" Pharmaceutical Sciences Poster Day, University at Buffalo (2011)
  • "Physiologically-Based Pharmacokinetics and Interactions of Everolimus and Sorafenib in Mice" American Association for Cancer Research, AACR (2011)
  • "Mechanism-Based PK/PD Model of Pramlintide in Patients with Type 1 Diabetes" AAPS Annual Meeting and Exposition, AAPS (2010)
  • "Modeling chemotherapeutic interactions of sorafenib and everolimus effects on pancreatic cancer cells" AAPS Annual Meeting and Exposition, AAPS (2010)
  • "Pharmacodynamic Interaction of Everolimus and Sorafenib Using In Vitro Whole Blood Lymphocyte Proliferation" AAPS Annual Meeting and Exposition, AAPS (2010)
  • "Pharmacokinetic - Pharmacodynamic - Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-Induced Arthritis" AAPS Annual Meeting and Exposition, AAPS (2010)
  • "Pharmacokinetic-Pharmacodynamic-Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-Induced Arthritis" AAPS Annual Meeting and Exposition, AAPS (2010)
  • "Pharmacokinetics and Pharmacodynamics of Rosiglitazone in Type 2 Diabetic Goto-Gakizaki (GK) Rats" AAPS Annual Meeting and Exposition, AAPS (2010)
  • "The Development of Mechanistic Population Pharmacokinetic Models to Support the Development of Targeted Release Characteristics from Modified Release Dosage Forms" AAPS Annual Meeting and Exposition, AAPS (2010)
  • "Department Highlights & Introduction and Historical Perspectives of PK/PD" 12th Buffalo Pharmaceutics Symposium, University at Buffalo (2010)
  • "Pharmacokinetic/Pharmacodynamic modeling of GLP-1 in healthy rats" 12th Buffalo Pharmaceutics Symposium, University at Buffalo (2010)
  • "PK/PD Modeling of Etanercept" Meeting of the Center for Protein Therapeutics (2010)
  • "Pediatric Pharmacokinetics: Lithium, Baclofen, and Hydroxyurea" 2010 Best Pharmaceuticals for Children Act Annual Meeting, National Institute of Child Health and Human Development & National Institutes of Health (2010)
  • "Pharmacokinetic - Pharmacodynamic - Disease Progression Model for Effect of Etanercept in Lewis Rats with Collagen-Induced Arthritis" Annual Pharmaceutics Graduate Student Research Meeting (2010)
  • "Pharmacokinetics and Pharmacodynamics of Anti-CD3 Monoclonal Antibody, Otelixizumab in Subjects with Diabetes and Psoriasis" The Annual Meeting of the Population Approach Group in Europe, Population Approach Group in Europe (2010)
  • "Pharmacodynamic Interaction of Everolimus and Sorafenib Using In Vitro Whole Blood Lymphocyte Proliferation" Pharmacology Day 2010, University at Buffalo (2010)
  • "Target-Mediated Pharmacokinetic Modeling of Exendin-4 Disposition in Rats, Monkeys and Humans" Pharmacology Day 2010, University at Buffalo (2010)
  • "Various" Annual Course in PK/PD Modeling, University at Buffalo (2010)
  • "Research Perspectives of the UB Department of Pharmaceutical Sciences" SUNY Upstate Cancer Research Institute Workshop, SUNY Upstate Cancer Research Institute (2010)
  • "Systems Pharmacology of Anti-Inflammatory Effects of Corticosteroids" Mount Sinai School of Medicine Workshop, Mount Sinai School of Medicine (2010)
  • "PK/PD Modeling of Anti-Inflammatory Drug Effects" Drug Metabolism Department at Hoffman La Roche, Hoffman La Roche (2010)
  • "Assessing Drug Accumulation and Half-Lives During Multiple-Dosing Conditions" Annual Meeting of AAPS, AAPS (2009)
  • "Comparison of Liver and Muscle Genes for Presence of Circadian Rhythms" Annual Meeting of AAPS, AAPS (2009)
  • "Population Pharmacokinetic-Pharmacodynamic Model for the Triglyceride Lowering Effect of a PPAR Agonist: A Phase I Study" Annual Meeting of AAPS, AAPS (2009)
  • "Role of Sex (Gender) in Drug Kinetics and Dynamics" Frontier Science and Technology Research Foundation, Frontier Science and Technology Research Foundation (2009)
  • "Target-Mediated Pharmacokinetic Modeling of Exendin-4 Disposition in Rats, Monkeys and Humans" Annual Meeting of AAPS, AAPS (2009)
  • "Pharmacokinetic/Pharmacodynamic Modeling of Glucose Clamp Effects of Inhaled Insulin" American Conference on Pharmacometrics, ACoP (2009)
  • "Population PK/PD Modeling of the Effects of Vildagliptin on Active GLP-1, Glucose, and Insulin" American Conference on Pharmacometrics, ACoP (2009)
  • "Disease Progression Model in Type 2 Diabetic Rats" Pharmacology Day 2009 (2009)
  • "Disease Progression Model in Type 2 Diabetic Rats" Pharmacology Day 2009 (2009)
  • "Gene Expression as a Pharmacodynamic Marker" AAPS Workshop on Translational Biomarkers (2009)
  • "Mechanism-Based PK/PD Model of Pramlintide in Type 1 Diabetic Patients" Pharmacology Day 2009 (2009)
  • "Methods of Utilizing Baseline Values for Indirect Response Models" Pharmacology Day 2009 (2009)
  • "Model-Based Comparison of Binocrit and Erypo Pharmacokinetics after Repeated I.V. and S.C. Administration" WCN (World Congress of Nephrology) (2009)
  • "Role of Sex/Gender in Drug Kinetics and Dynamics" City-Wide Grand Rounds, Erie County Medical Center (2009)
  • "Systems pharmacology of anti-inflammatory effects of corticosteroids" Experimental Biology 2009 Meeting (2009)
  • "Animal Scaling of Pharmacokinetics and Pharmacodynamics" , Hoffman-LaRoche (2009)
  • "Pharmacokinetic and Pharmacodynamic Modeling of Anti-inflammatory Drugs" , Hoffman-LaRoche (2009)
  • "Disease Progression Model in Type 2 Diabetic Goto-Kakizaki Rats" American Association of Pharmaceutical Sciences Meeting (2008)
  • "Mechanism-Based Modeling of Leptin Production and Effect on Food Intake in Normal Wistar (CON) and Type 2 Diabetic Goto-Kakizki Rats (GK) on Different Diets" American Association of Pharmaceutical Sciences Meeting (2008)
  • "Mechanism-Based Pharmacokinetic Pharmacodynamic (PKPD) Model for the Inverse Inoculum Effect of Imipenem Against Psedomonas Aeruginosa" American Association of Pharmaceutical Sciences Meeting (2008)
  • "Modeling Sitagliptin Effects on Glucagon-Like Peptide 1 (GLP-1) and Glucose in Type 2 Diabetic Patients (T2DM)" American Association of Pharmaceutical Sciences Meeting (2008)
  • "Bioequivalence of Biosimilars - Is Pharmacodynamic Equivalence Sufficient?" Ehrlich II -2nd World Conference on Magic Bullets Celebrating the 100th Anniversary of the Nobel Prize Award to Paul Ehrlich (2008)
  • "Corticosteroids - Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, and Disease Progression" Ehrlich II -2nd World Conference on Magic Bullets Celebrating the 100th Anniversary of the Nobel Prize Award to Paul Ehrlich (2008)
  • "First-Dose Pharmacokinetics of Lithium Carbonate in Children and Adolescents" Annual Meeting of the American Academy of Child and Adolescent Psychiatry, AACAP (2008)
  • "Pharmacokinetic Pharmacodynamic Concepts" Ehrlich II -2nd World Conference on Magic Bullets Celebrating the 100th Anniversary of the Nobel Prize Award to Paul Ehrlich (2008)
  • "Exposure-Response Modeling" Land O'Lakes Conference on Drug Metabolism/Applied Pharmacokinetics, University of Wisconsin (2008)
  • "Multiple-Pool Lifespan Models for Neutropenia to Assess the Population Pharmacodynamics of Unbound Paclitaxel from Two Formulations in Cancer Patients" Quantitative and Systems Pharmacology Workshop, National Institute of General Medical Sciences (2008)
  • "Population PK/PD Modeling of Inhibition of Dipeptidyl Peptidase IV" Quantitative and Systems Pharmacology Workshop, National Institute of General Medical Sciences (2008)
  • "Systems PK/PD/PG/DIS model for anti-inflammatory effects of corticosteroids" Quantitative and Systems Pharmacology Workshop, National Institute of General Medical Sciences (2008)
  • "Utility of PK/PD modeling in drug development & PK/PD modeling of anti-inflammatory drugs." Merial Pharmaceuticals, Merial Pharmaceuticals (2008)
  • "Erythropoietin Receptor-Mediated Disposition and Dynamic Model for Human Recombinant Erythropoietin (rHuEPO)" AAPS Annual Meeting (2007)
  • "Characterization and application of a new model for the assessment of non-competitive drug-drug interactions" AAPS Annual Meeting (2006)
  • "Development of mathematical model for chemotherapy-induced anemia in rats and its application to selection of rHuEPO dosing strategy" AAPS Annual Meeting (2006)
  • "Population pharmacokinetic and pharmacodynamic modeling of a novel erythropoietin receptor agonist, HematideTM, in healthy volunteers" , AAPS Annual Meeting (2006)
See All (95 Total) >
Service Activities:
  • University of Buffalo, Search Committee for Dean, School of Pharmacy; Member (2013)
  • E Fund Proposal Review Committee; Member (2012)
  • Advisory Committee, Center for Clinical and Translational Research Grant Application; Member (2012)
  • Pilot Studies Oversight Review Committee; Member (2012)
  • Committee; AAPS/AACP NIH Research Task Force; Other (2011)
  • VPR External Advisory Committee; Medical College of Wisconsin; Member (2011)
  • External Reviewer, Promotion; Rutgers University, New Jersey; Other (2011)
  • External Reviewer, Promotion; Eschelman School of Pharmacy, University of North Carolina; Other (2011)
  • NIDDK - National Institute of Diabetes and Kidney Diseases Special Emphasis Panel; NIDDK - Grant Applicatins; Other (2011)
  • Program Project: Mechanisms of Drug Disposition During Pregnancy; NIH - Program Project Grant Applications: Mechanisms of Drug Disposition During Pregnancy; Other (2011)
  • RFA Panel: Developmental Pharmacology; NIH - RFA Panel: Developmental Pharmacology; Other (2011)
  • Special Review Committee for Glue Grants; NIH Served as chair for NIH Special Review Committee for Glue Grants, March 25, 2011; Other (2011)
  • Accreditation Review Committee; Member (2010)
  • NIH Committee Meeting - Bethesda, MD; Quantitative and Systems Pharmacology; Other (2010)
  • School of Pharmacy and Pharmaceutical Sciences Accreditation Review Committee - Organization and Management; Member (2010)
  • Reviewer; NIH Director's Opportunity 5 Themes General Basic Science; Other (2010)
  • Special Emphasis Panel; NIGMS; Other (2009)
  • Reviewer; National Institute of Diabetes and Digestive and Kidney Diseases; Other (2009)
  • International Scientifica Advisory Board; 6th International Symposium on Measurement and Kinetics of In Vivo Drug Effects, The Netherlands; Other (2009)
  • Planning Committee; Translational Biomarkers for Accelerating Drug Development: From Preclinical to Clinical; Other (2009)
  • Special Emphasis Panel; NIGMS; Other (2009)
  • Advisory Board, Center for Protein Therapeutics; Member (2008)
  • SUNY Distinguished Service Review Committee; Member (2008)
  • Organizing Committee; AAPS Workshop on Biomarkers and Drug Development; Member (2008)
  • MRBS Faculty Committee; Member (2007)
  • Organizing Committee; Workshop on Pharmacology and Systems Biology; Member (2007)
  • Selection Committee; Volwiler Award, Am Assn Coll Pharmacy; Other (2006)
  • School of Pharmacy Awards Committee; Member (2005)
  • Executive Committee; Member (2001)
  • School Promotions and Tenure Committee; Member (2001)

Clinical Specialties:
Clinical Offices:
Insurance Accepted:

bottom-left cornerbottom-right corner

Contact Information

404 Kapoor Hall
Buffalo, NY 14214-8033
Phone: (716) 645-2855
Email: wjjusko@buffalo.edu


Log in to Update Your Profile